Science Corporation Implants Vision Chip in First Patient With Stargardt Disease Science Corporation has successfully placed its PRIMA retinal prosthesis in a Stargardt disease patient at the Sydney Eye Hospital in Australia. During initial rehabilitation sessions, the patient was able to discern individual letters and read a complete word. A breakthrough in neurotechnology and ophthalmic medicine has emerged with the first surgical implantation of a sight-restoring microdevice into a person living with Stargardt disease. Developed by Science Corporation, the PRIMA retinal implant was fitted during a procedure conducted at the Sydney Eye Hospital in Australia in May as part of an active clinical trial. The patient made rapid progress during early rehabilitation appointments, recognizing a single letter during the opening session and successfully reading an entire word in the second. The milestone marks a major step forward against a condition long regarded by clinicians as incurable. Understanding Stargardt Disease and Outer Retina Damage Stargardt disease directly targets the outer layer of the retina, triggering the gradual degradation and death of photoreceptors, the specialized cells responsible for sensing incoming light. In many cases, the inner retina remains intact, leaving the biological pathways that convey visual signals to the brain undamaged. As photoreceptors fail, patients develop an expanding blind spot directly in the center of their visual field. Worldwide, roughly 150,000 individuals have lost their sight because of this degenerative genetic condition. Max Hodak, founder of Science Corporation, described the scientific foundation underpinning the technology, noting that the retina functions as an integral component of the central nervous system. In his view, cochlear devices, retinal systems, and motor prosthetics all represent different expressions of brain-computer interfaces. When treating the brain as an information processor, visual perception boils down to electrical activity moving along the optic nerve. Transmitting properly formatted electrical impulses through the optic nerve enables the brain to construct visual perception artificially. How the PRIMA Implant and Camera Glasses Function Receiving the device involves a surgical operation lasting approximately one hour. The surgeon positions a tiny microchip at the posterior wall of the eye, directly where the patient's native photoreceptors have decayed. Following recovery, the user wears specialized spectacles outfitted with an integrated camera. This camera captures the surrounding environment and beams the visual data directly to the implanted microchip, which takes over the role of artificial photoreceptors. The implant deployed in this trial measures two millimeters by two millimeters, giving the user a narrow perspective comparable to gazing through a drinking straw. It does not provide full-color, wide-angle sight, but instead projects a high-contrast, black-and-white visual patch directly within the central field of view. Because the contrast and edge definition are exceptionally sharp, the patient can resolve several letters simultaneously. Hardware Scaling and Future Human Trials Engineering teams are now focused on widening the visual boundary offered by the technology. Expanding the field of view requires designing larger hardware that conforms smoothly to the eye's natural curvature, alongside shrinking the microelectrodes to capture native levels of visual detail. Max Hodak indicated that development is progressing steadily, with a next-generation implant scheduled to enter human trials within the next year. Over the coming five years, the enterprise expects to approach the visual acuity of natural human sight. PRIMA already holds commercial authorization in Europe for treating individuals blinded by geographic atrophy, an advanced stage of age-related macular degeneration. The underlying technology is designed for broad deployment, and developers intend to validate its utility across multiple retinal conditions beyond geographic atrophy, including Stargardt disease. Science Corporation's Platform and Skull-Based Sensors Max Hodak launched Science Corporation in 2021 following his departure from Neuralink, aiming to advance the fields of neural engineering and brain-computer interfaces. Rather than moving straight to general computing peripherals, the company chose to prove clinical viability and establish financial sustainability by addressing vision loss first. Beyond ocular devices, the company is preparing brain-computer interface hardware designed to sit beneath the skull while resting gently atop the brain's surface. This configuration differs fundamentally from Neuralink's architecture, which penetrates deep into cerebral tissue. Placing the sensor across the cortical exterior could support new diagnostic monitoring methods for neurological issues, such as tracking brain tumor progression. Treating Strokes and Severe Neurodegenerative Illness The firm plans to disclose its initial major clinical program soon, targeting a widely recognized neurodegenerative disorder. Stroke rehabilitation forms another key research pillar. When a stroke damages or destroys localized brain regions, establishing synthetic pathways between two separate deep-brain structures could allow clinicians to graft entirely new cortical functional zones into the brain, a feat impossible with legacy electrode designs. Company leadership anticipates that brain-computer interfaces will eventually become common medical equipment for people reaching their 60s and 70s, rather than consumer gadgets for healthy 40-year-olds. The long-term objective centers on expanding the healthy human health span rather than merely lengthening biological life, while unraveling how biological brains produce consciousness to eventually build engineered brains. What this means for you The successful placement of retinal microchips offers practical hope for millions of visually impaired individuals dealing with conditions previously labeled untreatable. • For Patients: The technology restores basic functional sight to individuals suffering from Stargardt disease and geographic atrophy. Users gain the ability to read letters and recognize words, fostering greater day-to-day independence. • Surgical Procedure: Patients undergo an outpatient operation lasting approximately one hour to implant a two-millimeter chip behind the retina. Functional recovery requires camera-equipped eyewear and structured rehabilitation training. • Visual Constraints: The current hardware delivers a narrow, high-contrast monochrome image comparable to looking through a straw. Users cannot perceive full color or broad visual angles until next-generation models arrive. • Treatment Timeline: While PRIMA has secured commercial clearance in Europe for geographic atrophy, expanded trials are progressing in Australia. Broader global availability across multiple conditions is expected over the next five years. Why this happened Stargardt disease genetically destroys the photoreceptor cells in the outer retina, producing expanding central blindness. Science Corporation bypassed this organic breakdown by substituting damaged cells with a microscale electronic sensor. • Photoreceptor Degeneration: The genetic condition causes the progressive death of light-detecting cells, resulting in central visual loss. However, the inner retinal layer and optic nerve pathways often remain functional. • Synthetic Signaling: The human brain interprets vision purely as electrical potential transmitted through the optic nerve. Researchers recognized that an electronic implant could stimulate surviving nerve structures to transmit clear artificial visual signals. • Trial Expansion: Following regulatory commercialization in Europe for geographic atrophy, developers sought to determine whether the interface could assist incurable hereditary conditions. This led directly to the clinical trial milestone at the Sydney Eye Hospital in Australia. Questions & Answers 1. What is Stargardt disease and how does it affect vision? Stargardt disease damages the outer retina by killing off light-sensing cells, producing an expanding blind spot directly in the center of a person's visual field. 2. How long does the PRIMA surgical implantation procedure take? Surgeons place the tiny microchip into the posterior wall of the patient's eye during an operation lasting about one hour. 3. What type of vision does the current implant produce for the patient? The implant produces a sharp, high-contrast monochrome patch in the central visual field, creating an experience comparable to looking through a straw. 4. What early milestones did the first Stargardt trial patient achieve? The patient identified a single letter during the initial rehabilitation session and successfully read a complete word during the second appointment. 5. How many people are affected by Stargardt disease worldwide? Approximately 150,000 individuals across the globe have lost their visual acuity due to Stargardt disease. 6. When was Science Corporation founded and by whom? Max Hodak established Science Corporation in 2021 after departing from Neuralink. https://trendkia.com/en/ai/science-corporation-ne-pahali-bara-stargardt-bimari-ke-marija-ki-ankha-men-lagaya-roshani-lautane-vala-chipa-47549 TrendKia — Har trend, sabse pehle.